Join us at AACR Annual Meeting 2023
April 14 – 19 | Orlando, FL | Booth #2442
Labcorp Oncology is uniquely positioned to power better decisions in oncology, providing solutions that support each step of the care continuum. Speak to our diagnostic team about our comprehensive portfolio from centralized testing to kitted solutions for screening, diagnosis and prognosis, or meet with our drug development teams about our global oncology-specific expertise that helps advance development of cancer diagnostics, drugs and devices through the full drug development continuum with speed and efficiency.
-
Join our Spotlight Theater
The power of ctDNA testing in therapy selection and recurrence monitoringLiquid biopsy represents a transformation in the management of oncology patients given its potential to detect, characterize and monitor cancers earlier than can be achieved with conventional modalities. Due to its noninvasive nature, availability and accessibility, liquid biopsy offers an alternative sampling option when tissue is unavailable or insufficient.
In this symposium, we demonstrate the following:- The utility of an NGS-based ctDNA testing approach for therapy selection in advanced cancers
- Tissue-agnostic treatment response monitoring in patients with metastatic colorectal cancer and its prognostic value in guiding treatment decisions
April 18, 2023
10:00 - 11:00 AM
Room: Exhibit Hall Theater C -
Speakers
This Exhibitor Spotlight Theater is a promotional activity and is not approved for continuing education credit. The content of this Exhibitor Spotlight Theater and opinions expressed by presenters are those of the sponsor or presenter and are not of the American Association for Cancer Research® (AACR).
-
VIEW OUR POSTERS
Session Category: Tumor Biology
#37 A novel technique to preclinically assess the ability of targeted therapies to inhibit both primary and metastatic non-small cell lung carcinoma
Erin Trachet
Session Category: Tumor Biology
Session Title: Novel Models of Human Cancer
Location: Section 2
Poster Board Number: 5#41 Subcutaneous growth and immune cell profiling of BT-474 human breast carcinoma in triple immunodeficient mice from multiple commercial vendors
Justin Snider
Session Category: Tumor Biology
Session Title: Novel Models of Human Cancer
Location: Section 2
Poster Board Number: 9#2402 Fractionated dosing: A more clinically relevant approach to radiotherapy in preclinical tumor models
Kerry Ann Bright
Session Category: Tumor Biology
Session Title: Radiation Sciences
Location: Section 3
Poster Board Number: 2#4654 Differential immunomodulation following checkpoint blockade in the orthotopic ID8-luc ovarian model
Sheri Barnes
Session Category: Tumor Biology
Session Title: Inflammation and Tumor Progression
Location: Section 5
Poster Board Number: 11#4561 3D Reconstructed Pancreas: A model capturing the unique tumor microenvironment and stromal architecture of pancreatic cancer
Dr. Uihlein (Predictive Oncology)
Session Category: Tumor Biology
Session Title: 3D and Tissue Recombinant Models
Location: Section 2
Poster Board Number: 12#5945 Transcriptional analysis of TME in MC38 colon carcinoma model following checkpoint inhibition
Priyanka Singh
Session Category: Tumor Biology
Session Title: Tumor-Stromal Cell (Including Immune Cell) Interactions and Therapy Responses
Location: Section 7
Poster Board Number: 6Session Category: Experimental and Molecular Therapeutics
#589 Long-term acclimation of target cell lines to tumor microenvironment culture condition provides mechanistic insights into cell therapy effectiveness
James Lim (Xcell Bio)
Session Category: Experimental and Molecular Therapeutics
Session Title: Targeting the Tumor Microenvironment
Location: Section 20
Poster Board Number: 23
#2749 Preclinical assessment of chimeric antigen receptor (CAR) T persistence and functionality in the disseminated NALM6-Luc human B cell acute lymphoblastic leukemia (ALL) model
Dave Draper
Session Category: Experimental and Molecular Therapeutics
Session Title: Innovative Assay Technologies
Location: Section 17
Poster Board Number: 3#2762 Inhibition of Murine Myeloid Suppressor Cells Increases CD8+ T cell Activation in Vitro
Anita Zaitouna
Session Category: Experimental and Molecular Therapeutics
Session Title: Innovative Assay Technologies
Location: Section 17
Poster Board Number: 16Session Category: Immunology
#1782 Functional potency assay predicts CAR-T effectiveness in tumor microenvironment
Yelena Bronevetsky (Xcell Bio)
Session Category: Immunology
Session Title: CAR T-cell Therapy
Location: Section 22
Poster Board Number: 16Session Category: Clinical Research Excluding Trials
#3358 PLCRC-PROVENC3: Assessing the prognostic value of post-surgery liquid biopsy cell-free circulating tumor DNA in stage III colon cancer patients.
Carmen Rubio Alarcón
Session Category: Clinical Research Excluding Trials
Session Title: PO.CL01.16 - Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 3
Location: Section 43
Poster Board Number: 1
#5452 Complimentary use of DNA- and RNA-based NGS assays optimizes detection of clinically relevant translocations for comprehensive genomic profiling
Rongqin Ren
Session Category: Clinical Research Excluding Trials
Session Title: Biomarkers of Therapeutic Benefit 5
Location: Section 37
Poster Board Number: 2
#5587 Ultra-deep targeted sequencing of cell-free DNA and patient-matched white blood cells for treatment response evaluation in patients with metastatic colorectal cancer.
Iris van ‘t Erve
Session Category: Clinical Research Excluding Trials
Session Title: PO.CL01.17 - Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 4
Location: Section 41
Poster Board Number: 11
#5597 Enhanced detection and classification of cell-free DNA alterations through matched normal analyses with PGDx elio plasma complete
Tonya N. Watkins
Session Category: Clinical Research Excluding Trials
Session Title: PO.CL01.17 - Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 4
Location: Section 41
Poster Board Number: 21
#923 Genomic landscape of patients with non-small cell lung cancer.
Neeraj Kumar Singh
Session Category: Clinical Research Excluding Trials
Session Title: PO.CL11.01 - Analyses Using Clinical and Genomic Databases
Location: Section 38
Poster Board Number: 6Session Category: Experimental and Molecular Therapeutics
#6220 Development of a mutation profiling NGS assay to facilitate clinical decisions in hematologic malignancies.
Grant Hogg
Session Category: Experimental and Molecular Therapeutics
Session Title: DNA Repair / Molecular Classification of Tumors for Diagnostics, Prognostics, and Therapeutic Outcomes / Others
Location: Section 18
Poster Board Number: 22Session Category: Clinical Trials
#CT212 A ctDNA-directed, multi-center phase II study of molecular response adaptive immuno-chemotherapy in patients with non-small cell lung cancer: Analysis of Stage 1 of CCTG BR.36
Valsamo Anagnostou
Session Category: Clinical Trials
Session Title: PO.CT02.02 - Phase II Clinical Trials 2
Location: Section 47
Poster Board Number: 2
Get Email Updates
Stay current by signing up to receive the latest news and updates on tests and services.